Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 63c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $230.25 +1.92%
EPS Growth %: +174.9%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +174.9%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of ($8.25), $0.63 worse than the analyst estimate of ($7.62). Revenue for the quarter came in at $1.05 billion versus the consensus estimate of $1.04 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Axis Capital Limited Downgrades Tech Mahindra Ltd. (TECHM:IN) to Sell (4)
- Axis Capital Limited Upgrades Tata Technologies (TATATECH:IN) to Buy (1)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
